A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer. - Gurule NJ; McCoach CE; Hinz TK; Merrick DT; Van Bokhoven A; Kim J; Patil T; Calhoun J; Nemenoff RA; Tan AC; Doebele RC; Heasley LE (NPJ precision oncology, 2021)